FXR has emerged as a potential therapeutic target for cholestatic liver disorders (Stofan et al., 2020), and its agonists have gained approval for the treatment of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The gene discussed is NR1H4; the disease is primary biliary cholangitis.